Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6RZ9Q)

• Drug Name: Clonidine Drug Info
• Synonyms: clonidine; Clonidin; Duraclon; Chlornidinum; 4205-90-7; Catapres-TTS; Catarpresan; Catarpres; Adesipress; Catapres; Catapressan; Catapresan; ST 155BS; ST-155-BS; Clonidinum; Clonidina; Clonidinum [INN-Latin]; Clonidinhydrochlorid; CATAPRES-TTS-3; CATAPRES-TTS-1; CATAPRES-TTS-2; N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; Isoglaucon; 2-(2,6-Dichloroanilino)-2-imidazoline; Dixarit; SKF 34427; Catapres- TTS; Clonidina [INN-Spanish]; M-5041T; Hemiton; CLORPRES; clonidine (amino form); Adesipress; Clofenil; Clopheline; Duraclont; Gemiton; Klofelin; Klofenil; M 5041T; Catapres (TN); Catarpres-TTS; ST-155BS; Tenso-Timelets; Catarpres-TTS (TN); Clonidine [USAN:BAN:INN]; Clonidine (JAN/USAN/INN); 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-(9CI); 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine; 2,6-dichloro-N-(2-imidazolidinylidene)aniline; 2,6-dichloro-N-2-imidazolidinylidenebenzenamide; 2,6-dichloro-N-imidazolidin-2-ylideneaniline; 2-((2,6-Dichlorophenyl)imino)imidazolidine; 2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2);2-(2,6-Dichloroanilino)-2-imidazoline; 2-(2,6-Dichlorophenylamino)-2-imidazoline; 2-(2,6-Dichlorophenylimino)imidazolidine; 2-Imidazoline, 2-(2,6-dichloroanilino)-(7CI,8CI); 2-[(2,6-Dichlorophenyl)imino]imidazoline; 2-[(2,6-dichlorophenyl)imino]-2-imidazoline; 734571A; 2,6-DICHLORO-N-IMIDAZOLIDIN-2-YLIDENEANILINE

Indication

Disease Entry	ICD 11	Status	REF
Attention deficit hyperactivity disorder	6A05.Z	Approved	[1]
Hypertension	BA00-BA04	Approved	[2]
Neonatal abstinence syndrome		Approved	[1]
Diabetic neuropathy	8C0Z	Phase 3	[3]

• Therapeutic Class: Antihypertensive Agents
• Cross-matching ID:
  PubChem CID: 2803
  ChEBI ID: CHEBI:3757
  CAS Number: CAS 4205-90-7
  TTD Drug ID: DM6RZ9Q
  VARIDT Drug ID: DR00521
  INTEDE Drug ID: DR0352
  ACDINA Drug ID: D00141

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor Alpha-2 (ADRA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meperidine	DMX4GND	Pain	MG30-MG3Z	Approved	[12]
Lofexidine	DM1WXA6	Heroin and opiate withdrawal	6C43	Approved	[13]
Sodium chloride	DMM3950	Skin burns	ME65.0	Approved	[4]
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[14]
Dexmedetomidine	DM93L4X	Irritability	MB24	Approved	[15]
Yohimbine	DMJCP1Y	Erectile dysfunction	HA01.1	Approved	[16]
Guanabenz	DM5QWEL	High blood pressure	BA00	Approved	[17]
Tizanidine	DMR2IQ4	Spasm	MB47.3	Approved	[18]
Oxymetazoline	DM8ZXT6	Arrhythmia	BC9Z	Approved	[19]
Brimonidine	DMQLT4N	Ocular hypertension	9C61.01	Approved	[20]

Drug(s) Targeting Membrane copper amine oxidase (AOC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydralazine	DMU8JGH	Chronic heart failure	BD1Z	Approved	[21]
ASP8232	DMYK1JU	Diabetic macular edema	9B71.02	Phase 2	[3]
BTT-1023	DMIEPJG	Psoriasis vulgaris	EA90	Phase 2	[22]
BI 1467335	DMTE3UV	Diabetic retinopathy	9B71.0	Discontinued in Phase 2	[23]
Vapaliximab	DM73EPK	Inflammation	1A00-CA43.1	Terminated	[24]
Vapill	DM30E56	Diabetic complication	5A2Y	Investigative	[25]
PSX-4206	DMVJDCM	Pulmonary disease	1B10-1F85	Investigative	[25]
RTU-1096	DMWVBD9	Atopic dermatitis	EA80	Investigative	[25]
FP-1102	DMGID4T	Vascular disease	BE2Z	Investigative	[25]
6-hydroxydopa quinone	DM7M58P	Discovery agent	N.A.	Investigative	[26]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[27]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[28]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[29]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[30]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[29]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[29]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[31]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[29]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[32]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[33]

Drug(s) Transported By Organic cation transporter 2 (SLC22A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[34]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[35]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[36]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[37]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[38]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[6]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[39]
Metformin	DM89QE1	Colorectal carcinoma		Approved	[40]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[41]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[42]

Drug(s) Transported By Organic cation transporter 3 (SLC22A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[6]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[38]
Metformin	DM89QE1	Colorectal carcinoma		Approved	[43]
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[44]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[38]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[38]
Amphetamine	DMSZQAK	Attention deficit hyperactivity disorder	6A05.Z	Approved	[45]
Acetylcholine	DMDF79Z	Cataract	9B10	Approved	[46]
Sodium chloride	DMM3950	Skin burns	ME65.0	Approved	[47]
Etilefrine	DM67PWD	Cardiovascular disease	BA00-BE2Z	Withdrawn from market	[48]

Drug(s) Transported By Organic cation transporter 1 (SLC22A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[34]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[49]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[50]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[51]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[27]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[52]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[53]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[54]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[55]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[6]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[56]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[57]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[58]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[59]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[61]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[62]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[63]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[57]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[64]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[91]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[92]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[93]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[94]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[95]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[95]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[96]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[97]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[98]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[99]

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[65]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[66]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[67]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[68]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[69]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[70]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[62]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[71]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[72]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[73]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[100]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[100]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[100]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[101]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[102]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[103]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[104]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[105]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[106]
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[107]

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[74]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[75]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[76]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[64]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[77]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[78]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[79]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[80]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[81]

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[82]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[83]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[84]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[85]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[86]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[87]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[88]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[89]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[90]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[85]

Drug(s) Affected By G protein-activated inward rectifier potassium channel 1 (KCNJ3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[11]
Haloperidol	DM96SE0	Delirium		Approved	[11]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[11]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[108]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[109]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[110]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[111]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[112]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[113]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[114]

Drug(s) Affected By Apoptosis-inducing factor 1, mitochondrial (AIFM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[115]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[116]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[117]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[118]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[119]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[120]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[121]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[122]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[123]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[124]

Drug(s) Affected By Renin (REN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[125]
Acebutolol	DM0TI4U	Hypertension	BA00-BA04	Approved	[126]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[127]
Reboxetine	DM26PRD	Depression	6A70-6A7Z	Approved	[128]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[129]
Ramipril	DM2R68E	Acute heart failure	BD10-BD13	Approved	[130]
Rhucin	DM3ADGP	Erectile dysfunction	HA01.1	Approved	[131]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[132]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[133]
Chlorthalidone	DM4DMBT	Edema	MG29	Approved	[134]

Drug(s) Affected By Pro-opiomelanocortin (POMC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[135]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[136]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[137]
Fentanyl	DM8WAHT	Analgesia	MB40.8	Approved	[138]
Cyproheptadine	DM92AH3	Allergic rhinitis	CA08.0	Approved	[139]
Triamcinolone	DM98IXF	Acute adrenal insufficiency		Approved	[140]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[141]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[142]
Metyrapone	DMI7FVQ	Cushing disease	5A70	Approved	[143]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[144]

Drug(s) Affected By Prolactin (PRL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[145]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[146]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[147]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[148]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[149]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[150]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[151]
Aripiprazole	DM3NUMH	Bipolar I disorder		Approved	[152]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[153]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[154]

Drug(s) Affected By Somatotropin (GH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Polyethylene glycol	DM4I1JP	Constipation	DD91.1	Approved	[155]
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[156]
Cyproheptadine	DM92AH3	Allergic rhinitis	CA08.0	Approved	[139]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[124]
Sodium oxybate	DMBOV5P	Narcolepsy	7A20	Approved	[157]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[155]
Connexyn	DMF29Q5	Attention deficit hyperactivity disorder	6A05.Z	Approved	[158]
Gamma Hydroxybutyric Acid	DMGBKVD	Narcolepsy	7A20	Approved	[159]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[160]
Octreotide	DMHIDCJ	Acromegaly	5A60.0	Approved	[161]

Drug(s) Affected By Insulin (INS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[162]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[149]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[163]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[164]
Fructose	DM43AN2	Vomiting	MD90	Approved	[165]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[166]
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[167]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[168]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[169]
Glibenclamide	DM8JXPZ	Diabetic complication	5A2Y	Approved	[167]

Drug(s) Affected By Apolipoprotein A-I (APOA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[170]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[171]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[172]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[173]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[174]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[175]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[123]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[176]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[177]
Gemfibrozil	DMD8Q3J	Hyperlipidaemia	5C80	Approved	[178]

Drug(s) Affected By Apolipoprotein A-II (APOA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[172]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[179]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[180]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[123]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[181]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[180]
Atenolol	DMNKG1Z	Angina pectoris	BA40	Approved	[9]
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[180]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[182]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[183]

Drug(s) Affected By Apoptosis regulator Bcl-2 (BCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[184]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[185]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[186]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[187]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[11]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[188]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[189]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[190]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[191]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[192]

Drug(s) Affected By Tumor necrosis factor alpha-induced protein 3 (TNFAIP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[193]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[188]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[194]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[195]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[196]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[193]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[197]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[198]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[199]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[200]

Drug(s) Affected By Interleukin-10 (IL10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[201]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[202]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[203]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[204]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[205]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[206]
Bisoprolol	DM3UZ95	Hypertension	BA00-BA04	Approved	[207]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[208]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[209]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[210]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[211]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[212]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[213]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[214]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[215]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[216]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[217]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[218]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[219]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[220]

Drug(s) Affected By Caspase-2 (CASP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[190]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[221]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[222]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[223]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[224]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[225]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[226]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[227]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[228]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[229]

Drug(s) Affected By Caspase-9 (CASP9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[228]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[230]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[188]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[190]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[231]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[232]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[117]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[233]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[234]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[235]

Drug(s) Affected By Tumor protein D52 (TPD52)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[193]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[236]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[193]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[237]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[238]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[229]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[124]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[239]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[240]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[241]

Drug(s) Affected By Caspase-8 (CASP8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[242]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[243]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[244]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[245]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[246]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[247]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[117]
Selenium	DM25CGV	N. A.	N. A.	Approved	[248]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[234]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[149]

Drug(s) Affected By Programmed cell death protein 4 (PDCD4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[193]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[249]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[250]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[193]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[251]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[237]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[252]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[253]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[254]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[227]

Drug(s) Affected By Bcl2-associated agonist of cell death (BAD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[255]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[220]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[245]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[256]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[257]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[258]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[172]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[259]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[225]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[260]

Drug(s) Affected By Delta-type opioid receptor (OPRD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[124]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[112]
Pilocarpine	DMV9ADG	Glaucoma/ocular hypertension	9C61	Approved	[11]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[261]
DPDPE	DMIRSNA	Discovery agent	N.A.	Investigative	[262]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[115]
paraquat	DMR8O3X	Discovery agent	N.A.	Investigative	[263]

Drug(s) Affected By Myeloperoxidase (MPO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[11]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[264]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[11]
Sulfamethoxazole	DMB08GE	Acute otitis media	AB00	Approved	[11]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[265]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[266]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[267]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[268]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]
Propylthiouracil	DM6D7N8	Hyperthyroidism	5A02	Approved	[270]

Drug(s) Affected By Kappa-type opioid receptor (OPRK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[149]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[271]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[272]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[181]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[142]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[273]
Morphine	DMRMS0L	Advanced cancer	2A00-2F9Z	Approved	[274]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[272]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[275]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[276]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor Alpha-2 (ADRA2)	TTQ8AFT	NOUNIPROTAC	Agonist	[4]
Membrane copper amine oxidase (AOC3)	TT7HC21	AOC3_HUMAN	Inhibitor	[5]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 3 (SLC22A3)	DT6201N	S22A3_HUMAN	Substrate	[6]
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[6]
Organic cation transporter 2 (SLC22A2)	DT9IDPW	S22A2_HUMAN	Substrate	[6]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[8]
Cytochrome P450 1A2 (CYP1A2) Main DME	DEJGDUW	CP1A2_HUMAN	Substrate	[8]
Cytochrome P450 3A5 (CYP3A5) Main DME	DEIBDNY	CP3A5_HUMAN	Substrate	[8]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Apolipoprotein A-I (APOA1)	OT5THARI	APOA1_HUMAN	Gene/Protein Processing	[9]
Apolipoprotein A-II (APOA2)	OTQ3HGTC	APOA2_HUMAN	Gene/Protein Processing	[9]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[10]
Apoptosis-inducing factor 1, mitochondrial (AIFM1)	OTKPWB7Q	AIFM1_HUMAN	Gene/Protein Processing	[10]
Bcl2-associated agonist of cell death (BAD)	OT63ERYM	BAD_HUMAN	Gene/Protein Processing	[10]
Caspase-2 (CASP2)	OTUDYSPP	CASP2_HUMAN	Gene/Protein Processing	[10]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[10]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Gene/Protein Processing	[10]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Gene/Protein Processing	[10]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Drug Response	[11]

References

• [1] Clonidine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 516).
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
• [5] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [6] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [7] Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
• [8] CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
• [9] The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. Am Heart J. 1990 Jul;120(1):172-9. doi: 10.1016/0002-8703(90)90175-w.
• [10] Clonidine Induces Apoptosis of Human Corneal Epithelial Cells through Death Receptors-Mediated, Mitochondria-Dependent Signaling Pathway. Toxicol Sci. 2017 Mar 1;156(1):252-260. doi: 10.1093/toxsci/kfw249.
• [11] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [12] Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7.
• [13] Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6.
• [14] Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
• [15] Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95.
• [16] Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9.
• [17] Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5.
• [18] Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52.
• [19] Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
• [20] Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90.
• [21] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [22] Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation. J Nucl Med. 2013 Aug;54(8):1315-9.
• [23] Clinical pipeline report, company report or official report of Boehringer Ingelheim.
• [24] Clinical pipeline report, company report or official report of Huginonline.
• [25] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767).
• [26] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [27] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [28] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [29] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [30] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [31] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [32] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [33] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [34] Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
• [35] Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
• [36] Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
• [37] Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
• [38] Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
• [39] The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
• [40] Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
• [41] A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
• [42] Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet. 2010;25(4):328-34.
• [43] Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009 Oct;50(4):1227-40.
• [44] Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
• [45] Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9.
• [46] Organic cation transporters: physiology, toxicology and special focus on ethidium as a novel substrate. Curr Drug Metab. 2009 Jul;10(6):617-31.
• [47] Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci. 2004 Mar 17;24(11):2846-51.
• [48] Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60.
• [49] Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
• [50] Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
• [51] Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
• [52] Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
• [53] Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
• [54] Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
• [55] Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
• [56] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [57] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [58] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [59] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [60] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [61] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [62] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [63] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [64] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [65] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [66] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [67] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [68] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [69] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [70] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [71] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [72] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [73] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [74] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [75] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [76] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [77] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [78] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [79] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [80] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [81] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [82] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [83] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [84] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [85] Drug Interactions Flockhart Table
• [86] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [87] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [88] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [89] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [90] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [91] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [92] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [93] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [94] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [95] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [96] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [97] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [98] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [99] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [100] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [101] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [102] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [103] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [104] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [105] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [106] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [107] Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA. 2006 Mar 8;295(10):1135-41. doi: 10.1001/jama.295.10.1135.
• [108] Atrial-like Engineered Heart Tissue: An In?Vitro Model of the Human Atrium. Stem Cell Reports. 2018 Dec 11;11(6):1378-1390. doi: 10.1016/j.stemcr.2018.10.008. Epub 2018 Nov 8.
• [109] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [110] Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines. BMC Cancer. 2004 Dec 16;4:93. doi: 10.1186/1471-2407-4-93.
• [111] The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
• [112] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [113] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [114] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [115] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [116] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [117] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [118] Sulindac activates nuclear translocation of AIF, DFF40 and endonuclease G but not induces oligonucleosomal DNA fragmentation in HT-29 cells. Life Sci. 2005 Sep 2;77(16):2059-70. doi: 10.1016/j.lfs.2005.04.021.
• [119] Quercetin induced cell apoptosis and altered gene expression in AGS human gastric cancer cells. Environ Toxicol. 2018 Nov;33(11):1168-1181. doi: 10.1002/tox.22623. Epub 2018 Aug 27.
• [120] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [121] Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53. Clin Cancer Res. 2004 May 1;10(9):3179-88. doi: 10.1158/1078-0432.ccr-03-0309.
• [122] Ouabain induces apoptotic cell death in human prostate DU 145 cancer cells through DNA damage and TRAIL pathways. Environ Toxicol. 2019 Dec;34(12):1329-1339. doi: 10.1002/tox.22834. Epub 2019 Aug 21.
• [123] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [124] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [125] Effects of histamine H2-receptor blockade on the cardiovascular reflex response to lower-body negative pressure in man. Acta Physiol Scand. 1990 May;139(1):161-72. doi: 10.1111/j.1748-1716.1990.tb08909.x.
• [126] Addition of acebutolol to diuretics in hypertension. Clin Pharmacol Ther. 1981 Dec;30(6):739-44. doi: 10.1038/clpt.1981.232.
• [127] Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients. Eur J Clin Pharmacol. 1986;29(5):523-7. doi: 10.1007/BF00635887.
• [128] Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension. 2006 Jul;48(1):120-6. doi: 10.1161/01.HYP.0000225424.13138.5d. Epub 2006 May 22.
• [129] Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med. 1990 Sep;89(3):313-21. doi: 10.1016/0002-9343(90)90344-d.
• [130] Effects of an angiotensin converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteers. off. Br J Clin Pharmacol. 1992 Sep;34(3):224-30. doi: 10.1111/j.1365-2125.1992.tb04128.x.
• [131] Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol. 2005 May;288(5):F1044-52. doi: 10.1152/ajprenal.00142.2004. Epub 2004 Dec 21.
• [132] beta-Endorphin and essential hypertension: importance of the clonidine-naloxone interaction. Acta Physiol Hung. 1985;65(2):217-26.
• [133] Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983 Dec 8;309(23):1414-9. doi: 10.1056/NEJM198312083092303.
• [134] Detection of low-renin hypertension; evaluation of out-patient renin-stimulating methods. Clin Sci Mol Med. 1975 Feb;48(2):91-6. doi: 10.1042/cs0480091.
• [135] Neuroendocrine effects of citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans. J Endocrinol Invest. 2010 Oct;33(9):657-62. doi: 10.1007/BF03346666. Epub 2010 Apr 22.
• [136] Prednisone effects on neurochemistry and behavior. Preliminary findings. Arch Gen Psychiatry. 1990 Oct;47(10):963-8. doi: 10.1001/archpsyc.1990.01810220079010.
• [137] Endogenous opioids modulate the cardiovascular response to mental stress. Psychoneuroendocrinology. 1990;15(3):185-92. doi: 10.1016/0306-4530(90)90029-9.
• [138] Serum beta-endorphin response to stress before and after operation under fentanyl anesthesia in neonates, infants and preschool children. Eur J Pediatr Surg. 2010 Mar;20(2):106-10. doi: 10.1055/s-0029-1243620. Epub 2010 Jan 18.
• [139] [Toxicity of cyproheptadine. Side effects and accidental overdosage (author's transl)]. Monatsschr Kinderheilkd (1902). 1978 Mar;126(3):123-6.
• [140] Steroid myopathy induced by epidural triamcinolone injection. Br J Rheumatol. 1995 Apr;34(4):385-6. doi: 10.1093/rheumatology/34.4.385.
• [141] Hormonal responses to the 5-HT1A agonist buspirone in remitted endogenous depressive patients after long-term imipramine treatment. Psychoneuroendocrinology. 2010 May;35(4):481-9. doi: 10.1016/j.psyneuen.2009.08.012. Epub 2009 Sep 16.
• [142] The role of acetaldehyde in mediating effects of alcohol on expression of endogenous opioid system genes in a neuroblastoma cell line. FASEB J. 2008 Mar;22(3):662-70. doi: 10.1096/fj.07-8346com. Epub 2007 Oct 12.
• [143] Mineralocorticoid receptor function in posttraumatic stress disorder after pretreatment with metyrapone. Biol Psychiatry. 2006 Oct 1;60(7):784-7. doi: 10.1016/j.biopsych.2006.01.014. Epub 2006 Mar 29.
• [144] [Melatonin reduces cortisol response to ACTH in humans]. Rev Med Chil. 2008 Nov;136(11):1390-7. doi: 10.4067/s0034-98872008001100004.
• [145] Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. Ann Pharmacother. 1995 Oct;29(10):999-1001. doi: 10.1177/106002809502901009.
• [146] [Impotence and gynecomastia secondary to hyperprolactinemia induced by ranitidine]. Therapie. 1994 Jul-Aug;49(4):361-2.
• [147] Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. doi: 10.1016/j.mce.2005.04.008.
• [148] Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain. 2009 Feb;132(Pt 2):392-401. doi: 10.1093/brain/awn326. Epub 2009 Jan 19.
• [149] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [150] The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report. Gen Hosp Psychiatry. 1985 Oct;7(4):364-6. doi: 10.1016/0163-8343(85)90053-2.
• [151] Influence of naloxone on muscle sympathetic nerve activity, systemic and calf haemodynamics and ambulatory blood pressure after exercise in mild essential hypertension. J Hypertens. 1995 Apr;13(4):447-61.
• [152] The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.
• [153] Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun;67(6):952-7. doi: 10.4088/jcp.v67n0612.
• [154] Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. J Rheumatol. 1985 Oct;12(5):990-1.
• [155] Metal-catalyzed oxidation of human growth hormone: modulation by solvent-induced changes of protein conformation. J Pharm Sci. 2001 Jan;90(1):58-69. doi: 10.1002/1520-6017(200101)90:1<58::aid-jps7>3.0.co;2-w.
• [156] Phosphatidylinositol 4-OH kinase is a downstream target of neuronal calcium sensor-1 in enhancing exocytosis in neuroendocrine cells. J Biol Chem. 2003 Feb 21;278(8):6075-84. doi: 10.1074/jbc.M204702200. Epub 2002 Dec 5.
• [157] Failure of gammahydroxy butyric acid to stimulate growth hormone secretion in cocaine addicts. Neuropeptides. 1997 Oct;31(5):459-62. doi: 10.1016/s0143-4179(97)90040-8.
• [158] Effect of centrally acting alpha-adrenergic agonists on sympathetic nervous system function in humans. Hypertension. 1984 Sep-Oct;6(5 Pt 2):II57-62. doi: 10.1161/01.hyp.6.5_pt_2.ii57.
• [159] Thyrotropin-releasing hormone-induced GH release after cocaine withdrawal in cocaine addicts. Neuropeptides. 1999 Dec;33(6):522-5. doi: 10.1054/npep.1999.0773.
• [160] Effects of cortisol and cocaine on plasma prolactin and growth hormone levels in cocaine-dependent volunteers. Addict Behav. 2005 May;30(4):859-64. doi: 10.1016/j.addbeh.2004.08.019.
• [161] Effect of a somatostatin analogue, octreotide, on renal haemodynamics and albuminuria in acromegalic patients. Eur J Clin Invest. 1992 Jul;22(7):494-502. doi: 10.1111/j.1365-2362.1992.tb01496.x.
• [162] Amino acid polymorphisms in the ATP-regulatable inward rectifier Kir6.2 and their relationships to glucose- and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM. Diabetes. 1997 Mar;46(3):508-12. doi: 10.2337/diab.46.3.508.
• [163] A receptor mechanism for the inhibition of insulin release by epinephrine in man. J Clin Invest. 1967 Jan;46(1):86-94. doi: 10.1172/JCI105514.
• [164] Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension. 1999 Jul;34(1):83-8. doi: 10.1161/01.hyp.34.1.83.
• [165] Quinapril treatment restores the vasodilator action of insulin in fructose-hypertensive rats. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):381-5. doi: 10.1046/j.1440-1681.2002.03668.x.
• [166] Retinoic acid can induce markers of endocrine transdifferentiation in pancreatic ductal adenocarcinoma: preliminary observations from an in vitro cell line model. J Clin Pathol. 2006 Jun;59(6):603-10. doi: 10.1136/jcp.2005.032003. Epub 2006 Feb 10.
• [167] Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications. 2005 Jan-Feb;19(1):60-4. doi: 10.1016/j.jdiacomp.2004.05.001.
• [168] Beta-adrenergic contribution to glucagon-induced glucose production and insulin secretion in uremia. Am J Physiol. 1986 Sep;251(3 Pt 1):E322-7. doi: 10.1152/ajpendo.1986.251.3.E322.
• [169] Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism. Horm Metab Res. 1998 Oct;30(10):642-5. doi: 10.1055/s-2007-978950.
• [170] Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis. 2002 Jul;163(1):59-68. doi: 10.1016/s0021-9150(01)00754-7.
• [171] Quercetin represses apolipoprotein B expression by inhibiting the transcriptional activity of C/EBP. PLoS One. 2015 Apr 15;10(4):e0121784. doi: 10.1371/journal.pone.0121784. eCollection 2015.
• [172] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [173] Effect of glucosamine on apolipoprotein AI mRNA stabilization and expression in HepG2 cells. Metabolism. 2004 Jun;53(6):766-71. doi: 10.1016/j.metabol.2003.11.027.
• [174] Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.
• [175] Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1336-41. doi: 10.1161/ATVBAHA.109.192088. Epub 2009 Aug 10.
• [176] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [177] Hepatic apolipoprotein A-I gene expression in patients with cholesterol gallstones treated with ursodeoxycholic acid. Ann Hepatol. 2002 Apr-Jun;1(2):85-9.
• [178] Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1783-9. doi: 10.1161/hq1001.096624.
• [179] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [180] Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor. Mol Cell Biol. 1996 Jul;16(7):3350-60. doi: 10.1128/MCB.16.7.3350.
• [181] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [182] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [183] Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension. Angiology. 1991 Sep;42(9):681-90. doi: 10.1177/000331979104200901.
• [184] 4.8% sevoflurane induces activation of autophagy in human neuroblastoma SH-SY5Y cells by the AMPK/mTOR signaling pathway. Neurotoxicology. 2022 May;90:256-264. doi: 10.1016/j.neuro.2022.04.008. Epub 2022 Apr 23.
• [185] Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
• [186] Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007 Jan;1095:35-44. doi: 10.1196/annals.1397.005.
• [187] Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
• [188] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [189] Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Toxicol In Vitro. 2018 Oct;52:306-313. doi: 10.1016/j.tiv.2018.07.001. Epub 2018 Jul 9.
• [190] Inhibition of caspase-dependent mitochondrial permeability transition protects airway epithelial cells against mustard-induced apoptosis. Apoptosis. 2006 Sep;11(9):1545-59. doi: 10.1007/s10495-006-8764-1.
• [191] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [192] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [193] Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci. 2011 Dec;124(2):278-90. doi: 10.1093/toxsci/kfr225. Epub 2011 Aug 27.
• [194] Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
• [195] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [196] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [197] Mapping the dynamics of Nrf2 antioxidant and NFB inflammatory responses by soft electrophilic chemicals in human liver cells defines the transition from adaptive to adverse responses. Toxicol In Vitro. 2022 Oct;84:105419. doi: 10.1016/j.tiv.2022.105419. Epub 2022 Jun 17.
• [198] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [199] The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol Appl Pharmacol. 2020 Mar 15;391:114915. doi: 10.1016/j.taap.2020.114915. Epub 2020 Feb 6.
• [200] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [201] Cytokine mRNA profiles in cultured human skin component cells exposed to various chemicals: a simulation model of epicutaneous stimuli induced by skin barrier perturbation in comparison with that due to exposure to haptens or irritant. J Dermatol Sci. 2001 Jun;26(2):85-93. doi: 10.1016/s0923-1811(00)00165-1.
• [202] Regulatory role of nitric oxide on monocyte-derived dendritic cell functions. J Interferon Cytokine Res. 2003 Aug;23(8):423-31. doi: 10.1089/107999003322277838.
• [203] Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol. 1999 Mar;30(3):376-82. doi: 10.1016/s0168-8278(99)80093-2.
• [204] Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology. 2009 Feb 27;256(3):183-90. doi: 10.1016/j.tox.2008.11.016. Epub 2008 Nov 28.
• [205] Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance. Clin Exp Immunol. 2010 Aug;161(2):298-305. doi: 10.1111/j.1365-2249.2010.04170.x. Epub 2010 May 18.
• [206] Quercetin's influence on exercise-induced changes in plasma cytokines and muscle and leukocyte cytokine mRNA. J Appl Physiol (1985). 2007 Nov;103(5):1728-35. doi: 10.1152/japplphysiol.00707.2007. Epub 2007 Aug 23.
• [207] The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines. Int J Clin Pharmacol Ther. 2009 Nov;47(11):686-94. doi: 10.5414/cpp47686.
• [208] [Effects of vitamin A on the differentiation, maturation and functions of dendritic cells from cord blood]. Zhonghua Er Ke Za Zhi. 2004 May;42(5):340-3.
• [209] Zinc induces chemokine and inflammatory cytokine release from human promonocytes. J Hazard Mater. 2011 Nov 30;196:335-41. doi: 10.1016/j.jhazmat.2011.09.035. Epub 2011 Sep 19.
• [210] Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
• [211] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [212] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [213] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [214] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [215] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [216] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [217] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [218] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [219] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [220] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [221] Carbamylation and oxidation of proteins lead to apoptotic death of lymphocytes. Chem Biol Interact. 2017 May 25;270:24-32. doi: 10.1016/j.cbi.2017.04.007. Epub 2017 Apr 8.
• [222] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [223] Actinomycin D and staurosporine, potent apoptosis inducers in vitro, are potentially effective chemotherapeutic agents against glioblastoma multiforme. Cancer Chemother Pharmacol. 2000;45(2):149-56. doi: 10.1007/s002800050023.
• [224] Quercetin-induced apoptosis of HL-60 cells by reducing PI3K/Akt. Mol Biol Rep. 2012 Jul;39(7):7785-93. doi: 10.1007/s11033-012-1621-0. Epub 2012 May 4.
• [225] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [226] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [227] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [228] Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology. 2003 Sep;144(9):3852-9. doi: 10.1210/en.2003-0098.
• [229] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [230] Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J Biol Chem. 2002 Jul 26;277(30):27393-400. doi: 10.1074/jbc.M201963200. Epub 2002 May 14.
• [231] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [232] The effects of quercetin in cultured human RPE cells under oxidative stress and in Ccl2/Cx3cr1 double deficient mice. Exp Eye Res. 2010 Jul;91(1):15-25.
• [233] Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro. J Biochem Mol Toxicol. 2022 Nov;36(11):e23185. doi: 10.1002/jbt.23185. Epub 2022 Aug 3.
• [234] Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer. 2002 Feb 1;86(3):443-8. doi: 10.1038/sj.bjc.6600079.
• [235] Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro. 2012 Aug;26(5):649-55. doi: 10.1016/j.tiv.2012.01.024. Epub 2012 Feb 8.
• [236] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [237] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [238] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [239] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [240] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [241] Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009 Aug 21;138(4):645-659. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.
• [242] Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
• [243] Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer. 2011 Apr 12;104(8):1278-87. doi: 10.1038/bjc.2011.84.
• [244] Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Mol Cancer. 2011 Jul 31;10:95. doi: 10.1186/1476-4598-10-95.
• [245] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [246] The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J Toxicol Sci. 2019;44(6):435-440. doi: 10.2131/jts.44.435.
• [247] Melatonin enhances hydrogen peroxide-induced apoptosis in human promyelocytic leukaemia HL-60 cells. Mol Cell Biochem. 2011 Jul;353(1-2):167-76. doi: 10.1007/s11010-011-0783-8. Epub 2011 Mar 23.
• [248] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [249] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [250] Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res. 2007 Jan;5(1):95-108. doi: 10.1158/1541-7786.MCR-06-0125.
• [251] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [252] Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells. J Biol Chem. 2015 Jun 19;290(25):15799-15811. doi: 10.1074/jbc.M115.641167. Epub 2015 May 11.
• [253] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [254] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [255] Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ. 2000 Jun;7(6):574-86. doi: 10.1038/sj.cdd.4400688.
• [256] Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells. Cancer Res. 2003 Feb 1;63(3):616-20.
• [257] Simvastatin induces activation of the serine-threonine protein kinase AKT and increases survival of isolated human pancreatic islets. Transplantation. 2002 Oct 27;74(8):1063-9. doi: 10.1097/00007890-200210270-00001.
• [258] Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). Mol Cell Biochem. 2010 Nov;344(1-2):173-84. doi: 10.1007/s11010-010-0540-4. Epub 2010 Jul 25.
• [259] Down regulation of N-acetylglucosaminyltransferase V facilitates all-transretinoic acid to induce apoptosis of human hepatocarcinoma cells. Mol Cell Biochem. 2006 Mar;284(1-2):103-10. doi: 10.1007/s11010-005-9022-5. Epub 2006 Jan 13.
• [260] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [261] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [262] Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine. J Med Chem. 2011 Oct 13;54(19):6531-7. doi: 10.1021/jm2003238. Epub 2011 Sep 7.
• [263] Proteasome subunit and opioid receptor gene expression down-regulation induced by paraquat and maneb in human neuroblastoma SH-SY5Y cells. Environ Toxicol Pharmacol. 2015 Nov;40(3):895-900. doi: 10.1016/j.etap.2015.09.019. Epub 2015 Oct 3.
• [264] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [265] An evaluation of myeloperoxidase-mediated bio-activation of NSAIDs in promyelocytic leukemia (HL-60) cells for potential cytotoxic selectivity. Toxicol Lett. 2017 Oct 5;280:48-56.
• [266] Differentiation between stoichiometric and anticatalytic antioxidant properties of benzoic acid analogues: a structure/redox potential relationship study. Chem Biol Interact. 2013 Nov 25;206(2):194-203.
• [267] Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
• [268] Effect of anti-rheumatic drugs on the release of lysosomal enzymes from human leukocytes. Z Rheumatol. 1984 Jan-Feb;43(1):23-6.
• [269] Benzodithiophenes induce differentiation and apoptosis in human leukemia cells. Cancer Res. 2005 Sep 1;65(17):7847-55. doi: 10.1158/0008-5472.CAN-05-1053.
• [270] Inhibition of oxidation activity of myeloperoxidase (MPO) by propylthiouracil (PTU) and anti-MPO antibodies from patients with PTU-induced vasculitis. Clin Immunol. 2007 Feb;122(2):187-93. doi: 10.1016/j.clim.2006.09.011. Epub 2006 Oct 27.
• [271] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [272] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [273] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [274] In vivo and in vitro evaluation of novel -opioid receptor agonist compounds. Eur J Pharmacol. 2015 Nov 15;767:193-200. doi: 10.1016/j.ejphar.2015.10.025. Epub 2015 Oct 20.
• [275] Effects of tobacco compounds on gene expression in fetal lung fibroblasts. Environ Toxicol. 2008 Aug;23(4):423-34.
• [276] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.